ERAS · Insider Trading
Erasca, Inc. Common Stock
Every open-market purchase and sale reported by ERAS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Charles S. Fuchs | President, R&D | A | +1,300,000 deriv. | — |
| 2026-06-29 | Julie Hambleton | Director | A | +29,888 deriv. | — |
| 2026-06-29 | Alexander W. Casdin | Director | A | +29,888 deriv. | — |
| 2026-06-29 | Pratik S Multani | Director | A | +29,888 deriv. | — |
| 2026-06-29 | James Arthur Bristol | Director | A | +29,888 deriv. | — |
| 2026-06-29 | Jean I Liu | Director | A | +29,888 deriv. | — |
| 2026-06-29 | Valerie Denise Harding Start | Director | A | +29,888 deriv. | — |
| 2026-04-03 | Ebun Garner | Chief Legal Officer | MIXED | — | −$1.18M |
| 2026-03-06 | Shannon Morris | Chief Medical Officer | MIXED | — | −$266.76K |
| 2026-01-30 | Jonathan E Lim | Chairman & CEO | A | +2,000,000 deriv. | — |
| 2026-01-30 | David M. Chacko | CFO and CBO | J | +17,793 | +$21.25K |
| 2026-01-30 | Shannon Morris | Chief Medical Officer | A | +625,000 deriv. | — |
| 2026-01-30 | Ebun Garner | General Counsel & Corp. Sec. | A | +560,000 deriv. | — |
| 2026-01-30 | Michael David Varney | Director | A | +96,000 deriv. | — |
| 2026-01-08 | Ebun Garner | General Counsel & Corp. Sec. | MIXED | +3,902 | −$462.15K |
| 2026-01-05 | Pratik S Multani | Director | A | +19,532 deriv. | — |
| 2026-01-05 | Jean I Liu | Director | A | +20,617 deriv. | — |
| 2026-01-05 | Alexander W. Casdin | Director | A | +23,872 deriv. | — |
| 2026-01-05 | James Arthur Bristol | Director | A | +37,762 deriv. | — |
| 2026-01-05 | Valerie Denise Harding Start | Director | A | +24,306 deriv. | — |
| 2025-06-26 | Michael David Varney | Director | A | +120,000 deriv. | — |
| 2025-06-26 | Valerie Denise Harding Start | Director | A | +120,000 deriv. | — |
| 2025-06-26 | Jean I Liu | Director | A | +120,000 deriv. | — |
| 2025-06-26 | Pratik S Multani | Director | A | +120,000 deriv. | — |
| 2025-06-26 | Alexander W. Casdin | Director | A | +120,000 deriv. | — |
| 2025-06-26 | James Arthur Bristol | Director | A | +120,000 deriv. | — |
| 2025-06-26 | Julie Hambleton | Director | A | +120,000 deriv. | — |
| 2025-06-03 | Pratik S Multani | Director | G | — | — |
| 2025-02-18 | Ebun Garner | General Counsel & Corp. Sec. | A | +50,000 deriv. | — |
| 2025-02-05 | Shannon Morris | Chief Medical Officer | A | +780,000 deriv. | — |
| 2025-02-05 | Jonathan E Lim | Chairman & CEO | A | +2,500,000 deriv. | — |
| 2025-02-05 | David M. Chacko | CFO and CBO | J | +15,461 | +$24.18K |
| 2025-02-05 | Ebun Garner | General Counsel & Corp. Sec. | J | +11,446 | +$17.90K |
| 2025-01-02 | Valerie Denise Harding Start | Director | A | +29,402 deriv. | — |
| 2025-01-02 | James Arthur Bristol | Director | A | +45,678 deriv. | — |
| 2025-01-02 | Alexander W. Casdin | Director | A | +28,877 deriv. | — |
| 2025-01-02 | Jean I Liu | Director | A | +24,939 deriv. | — |
| 2024-06-21 | Jonathan E Lim | Chairman & CEO | A | +632,759 deriv. | — |
| 2024-06-21 | Shannon Morris | Chief Medical Officer | A | +137,142 deriv. | — |
| 2024-06-21 | Pratik S Multani | Director | A | +60,000 deriv. | — |
| 2024-06-21 | Julie Hambleton | Director | A | +60,000 deriv. | — |
| 2024-06-21 | Ebun Garner | General Counsel & Corp. Sec. | A | +160,082 deriv. | — |
| 2024-06-21 | Jean I Liu | Director | A | +60,000 deriv. | — |
| 2024-06-21 | Valerie Denise Harding Start | Director | A | +60,000 deriv. | — |
| 2024-06-21 | Michael David Varney | Director | A | +60,000 deriv. | — |
| 2024-06-21 | David M. Chacko | CFO and CBO | A | +278,812 deriv. | — |
| 2024-06-21 | James Arthur Bristol | Director | A | +60,000 deriv. | — |
| 2024-06-21 | Alexander W. Casdin | Director | A | +60,000 deriv. | — |
| 2024-05-22 | Alexander W. Casdin | Director | Buy | +80,000 | +$181.92K |
| 2024-02-07 | Jonathan E Lim | Chairman & CEO | A | +1,500,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jonathan E Lim | Chairman & CEO | 19,456,216 | $283.28M |
| Alexander W. Casdin | Director | 667,724 | $9.72M |
| David M. Chacko | CFO and CBO | 279,980 | $4.08M |
| James Arthur Bristol | Director | 207,500 | $3.02M |
| Pratik S Multani | Director | 172,866 | $2.52M |
| Ebun Garner | Chief Legal Officer | 105,076 | $1.53M |
| Valerie Denise Harding Start | Director | 22,000 | $320.32K |
| Julie Hambleton | Director | 6,000 | $87.36K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ERAS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.